Based on these findings, a couple of proteins (e.g., N1 chemoattractants, osteopontin, and decorin) were identified with great immunotherapeutic potential to drive breast cancer metastatic dormancy, and a prediction model (N1-to-N2 chemoattractant ratio) was suggested to monitor the risk of metastatic outgrowth in the lungs and predict outcomes for breast cancer. The gene discussed is DCN; the disease is breast carcinoma.